NEWS & EVENTS
March 30th 2026
DisCoVery publishes an article on association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
The role of antiviral treatment in COVID-19 hospitalized patients remains controversial. In this study, we analyzed nasopharyngeal viral load and the clinical score of patients (as measured by the National Early Warning Score 2 (NEWS-2)) in the DisCoVeRy trial, where 664 patients were randomized to either standard of care (SoC) or SoC + remdesivir. We [...]
Read more
January 6th 2026
DisCoVeRy publishes the 15-months results of the evaluation of AZD7442 (tixagevimab/cilgavimab) in hospitalized COVID-19 patients, including clinical, safety, seroneutralization, immunogenicity, and pharmacokinetics data
AZD7442 is a cocktail of two monoclonal antibodies (mAbs), tixagevimab and cilgavimab, derived from B cells obtained from patients who had recovered from SARS-CoV2 infection. In this phase 3, double-blind, randomized, multicenter trial, hospitalized adults with PCR-confirmed SARS-CoV-2 infection were randomized to receive AZD7442 or placebo, and followed-up until day 456, with repeated blood sample [...]
Read more
December 9th 2025
Hydroxychloroquine Does Not Improve biomarkers of Vascular Damage or Blood Clotting in Hospitalized COVID-19 Patients
At the start of the COVID-19 pandemic, hydroxychloroquine (HCQ)—a drug commonly prescribed for autoimmune diseases and in particular antiphospholip syndrome—was considered a potential treatment due to its anti-inflammatory but also its supposed blood vessel-protective effects. Because severe COVID-19 induces damage to the blood vessels and abnormal blood clotting, we explored whether HCQ might offer vascular [...]
Read more
May 14th 2025
JAK Inhibitors for COVID-19: New Insights from an Individual Participant Data Meta-Analysis
Clinical guidelines have varied in interpreting evidence on JAK inhibitors for adults hospitalized due to COVID-19. Previous systematic reviews pooled six randomized trials, showing clinical benefits, but emphasized the need for more high-quality data especially regarding safety and certain subgroups. This study, published in The Lancet Respiratory Medicine and initiated by EU-RESPONSE, analyzed data from [...]
Read more
May 12th 2025
EU-RESPONSE third face-to-face consortium meeting
On 7 May 2025, the EU-RESPONSE consortium convened its third face-to-face meeting in the historic city of Verona. The event gathered approximately 60 participants, including project partners and invited external experts. Attendees engaged in dynamic and constructive discussions, reflecting on the project’s progress, key achievements, and strategic next steps. The meeting underscored the strong collaborative [...]
Read more
April 29th 2025
DisCoVeRy publishes an article on key outcome biomarker (sST2) in COVID-19
We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline levels of 21 biomarkers and time to hospital discharge and change in NEWS-2 score in patients from DisCoVeRy trial. We fitted multivariate models adjusted for baseline ISARIC [...]
Read more
April 15th 2025
EU-RESPONSE at ECCMID 2025
EU-RESPONSE was represented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID), held in Vienna from 11 to 15 April 2025. An oral presentation titled “Pharmacokinetics and immunogenicity of AZD7442 (tixagevimab/cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial” was delivered by Clément Massonnaud. Conclusions: To our knowledge, this is [...]
Read more
January 17th 2025
Survey: Databases for Target Trial Emulations
The EU-RESPONSE consortium is conducting a survey, endorsed by CoMeCT, to identify high-quality databases of hospitalized respiratory infectious disease patients. This survey project aims to strengthen global pandemic preparedness by creating a comprehensive overview of databases suitable for target trial emulations. While randomized controlled trials remain the gold standard for treatment evaluation, the urgent nature [...]
Read more
June 20th 2024
EU-RESPONSE second face-to-face consortium meeting
The EU-RESPONSE consortium held its second face-to-face consortium meeting in Madrid on 19-20 June, 2024. The event brought together around 50 attendees, including project partners, the chair of the EU-RESPONSE Scientific and Ethics Advisory Board, and other invited external experts. Participants engaged in productive discussions about the project's progress, achievements, and upcoming steps, highlighting the [...]
Read more
April 25th 2024
Coordination of COVID-19 platform trials in Europe
Coordination of COVID-19 platform trials in Europe To ensure optimal coordination of the EU-funded COVID-19 platform trials, a double coordination mechanism was established. It included the Trial Coordination Board (TCB) to promote the dialogue between investigators and relevant public health stakeholders and the Joint Access Advisory Mechanism (JAAM) to streamline access of new intervention arms [...]
Read more
February 15th 2024
DisCoVery publishes a letter on Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. There is ongoing need to urgently address the mAb treatment gap, particularly for immunocompromised patients. The unmet need is further highlighted by the DisCoVeRy Phase 3, adaptive, multicenter European, randomized, double-blind, superiority trial that evaluated the efficacy [...]
Read more
December 13th 2023
Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial The study aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with Coronavirus Disease 2019 (COVID-19) receiving remdesivir plus standard of care (SoC) compared to SoC alone (control), as an [...]
Read more
December 2nd 2023
Вавада казино возможности для азартных игроков
Вавада Казино Возможности Азартных Игроков Описание Вавада казино возможности для азартных игроков Если вы ищете азартные развлечения с высоким качеством сервиса и разнообразием игр, стоит обратить внимание на предложения, представленные в среде онлайн-игр. Платформы предоставляют множество шансов для получения удовольствия и выигрышей, поэтому стоит ознакомиться с актуальными вариантами. Среди многочисленных платформ, ваш выбор может пасть […]
October 11th 2023
DisCoVery publishes an article on association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
The role of antiviral treatment in COVID-19 hospitalized patients remains controversial. In this study, we analyzed nasopharyngeal viral load and the clinical score of patients (as measured by the National Early Warning Score 2 (NEWS-2)) in the DisCoVeRy trial, where 664 patients were randomized to either standard of care (SoC) or SoC + remdesivir. We [...]
Read more
September 15th 2023
EU-RESPONSE supports a global meta-analysis on JAK inhibitors in hospitalized COVID-19 patients
Several trial consortia, including EU RESPONSE, have investigated JAK inhibitors (such as baricitinib, ruxolitinib, and tofacitinib) for the treatment in patients hospitalized with COVID-19. However, these trials showed conflicting results, especially regarding specific subgroup of patients such as patients with co-morbidities. As part of EU RESPONSE’s effort to generate high-quality evidence for COVID-19 treatments, we [...]
Read more
September 14th 2023
Vavada kazino oficiālais saits un darba spogulis
Vavada kazino oficiālais saits un darba spogulis Vavada kazino oficiālais saits un darba spogulis Ja meklē ne tikai izklaidi, bet arī kvalitatīvu spēļu pieredzi, pievērs uzmanību pieejamajiem resursiem. Ieteicams izpētīt vavada online casino, kas piedāvā plašu spēļu klāstu un dažādas bonusu iespējas. Šajā vietnē varēsi atrast gan klasiskos, gan jaunākos spēļu automātus, kas garantē aizraujošu […]
July 21st 2023
Игровые автоматы Вавада на официальном сайте
Игровые автоматы Вавада официальный сайт обзор Игровые автоматы Вавада на официальном сайте Если вы ищете качественные и разнообразные возможности для азартных игр, стоит обратить внимание на платформу, которая предлагает широкий выбор игровых решений. Отличная репутация, надежность и удобный интерфейс создают комфортные условия для увлекательного времяпрепровождения. Это решение заслуживает вашего внимания уже сегодня. На ресурсе представлено […]
June 15th 2023
DisCoVery publishes an article on quality control in the context of the SARS-CoV 2 epidemic
Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20–15 DisCoVeRy study The study Sponsor is responsible for ensuring participants’ safety and reliability of the data collected, in particular through the monitoring carried out in the investigating centers. This article presents the experience of quality control assurance in [...]
Read more
June 5th 2023
DisCoVery publishes an article on management of pharmacovigilance during the COVID-19 pandemic crisis
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial During a pandemic crisis, sponsors should educate and train investigators about the importance of the pharmacovigilance issues. •The assessment of the safety profile of the investigational medicinal drug is [...]
Read more
May 31st 2023
Vavada registreerimise juhend ja praktilised soovitused
Vavada registreerimise juhend ja praktilised soovitused Vavada registreerimise juhend ja praktilised soovitused Alusta protsessi, otsustades, millised dokumendid sul vajalikud on. Kinnita oma isikut, et vältida hilisemaid probleeme ja saada täielikku kasu ulatuslikest boonustest. Oluline on valmistada ette nii isikut tõendav dokument kui ka tõend elukoha kohta, et registreerimine sujuks kiirelt. Ära unusta kasutada vavada promo […]
May 15th 2023
EU-RESPONSE first face-to-face consortium meeting
EU-RESPONSE first face-to-face consortium meeting was succesfully held in Oslo on 11-12 May 2023, in presence of the chair of EU-RESPONSE Scientific and Ethics Advisory Board and other invited external experts. Around 60 people attended in person to discuss the project progress, acheivements and next steps.
Read more
May 11th 2023
Wpływ Bony Vavada na wybór gier w Polsce w 2026 roku
Wpływ Bony Vavada na wybór gier w Polsce w 2026 roku Wpływ Bony Vavada na wybór gier w Polsce w 2026 roku Eksplorując opcje dostępne w kasynach internetowych, klienci coraz częściej zwracają uwagę na atrakcyjne oferty promocyjne. Wykorzystanie bonusów stało się kluczowym czynnikiem decyzyjnym, wpływającym na to, które platformy cieszą się popularnością wśród graczy. Dzieje […]
April 21st 2023
Вавада казино зеркало доступ к играм и слотам 2026
Вавада казино зеркало доступ к слотам и играм 2026 Вавада казино зеркало доступ к играм и слотам 2026 Для игроков, стремящихся к качественному развлечению, использование vavada вход предоставляет возможность быстро и без проблем попасть в мир азартных игр. Благодаря обновленным ссылкам, доступ к разнообразным автоматам и играм стал более стабильным. В 2026 году стоит обратить […]
January 13th 2023
EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients
EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients The first drug tested on EU-SolidAct is baricitinib, a tablet approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, have been published in Critical Care on January 10th [...]
Read more
March 7th 2022
EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial
EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial Based on recent results from the Recovery trial showing a mortality benefit for baricitinib in severe COVID-19, EU SolidAct has decided to stop inclusion of immunocompetent participants to the baricitinib trial. However, as the safety and benefit of immunomodulators including baricitinib is still not [...]
Read more
March 2nd 2022
remdesivir has a significant antiviral activity, reducing the amount of viral particles released by infected cells
An article published on 2 March in The Journal of Antimicrobial Chemotherapy, shows the effect of remdesivir on viral dynamics in COVID-19 hospitalized patients. The use of remdesivir has been associated to contradictory virological and clinical results in the past months. Here, we analyzed its effect on viral dynamics in the DisCoVeRy trial, where 665 [...]
Read more
January 27th 2022
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Bergen, Norway and Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients. The EU-SolidAct trial - European [...]
Read more
September 24th 2021
Remdesivir Ineffective in Patients Hospitalized With COVID-19 and the DisCoVeRy Trial Continues with a New Antiviral
The Discovery clinical trial was initially launched in France by Inserm in March 2020, to evaluate several possible treatments for COVID-19. Its European expansion was made possible by the EU-RESPONSE[1] project, funded by Europe. Interim analysis of the trial data had led to the recommendation to suspend the recruitment of remdesivir group patients for futility [...]
Read more
June 28th 2021
Launch of European Covid-19 trials coordination module website
Launch of European Covid-19 trials coordination module website. The coordination module of the EU-funded projects RECOVER1 and EU-RESPONSE2 has launched its website https://covid19trials.eu/en. It centralises information for academics and industry on access to the three large Pan-European adaptive platform trials currently underway: DisCoVeRy, EU-SolidAct & REMAP-CAP. A coordinated Pan-European approach is essential for tackling the [...]
Read more
May 28th 2021
EU SolidAct – a pan-European platform for pandemic research and preparedness
EU SolidAct - a pan-European platform for pandemic research and preparedness There is an urgent need for rapid and coordinated investigation of new candidate drugs during pandemics. EU-SolidAct is an Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with COVID-19 and to facilitate a joint European response to future pandemics. The first [...]
Read more
April 29th 2021
Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial
April 29, 2021 – A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19. It is planned to enroll 1240 patients across Europe in this Phase III clinical trial. With its wealth of experience in the domain of targeted therapies [...]
Read more
October 20th 2020
Launch of the EU-RESPONSE project
The EU-RESPONSE Kick-off meeting took place on October 20th 2020 via videoconference. This meeting gathered the whole EU-RESPONSE consortium to present and discuss the planned work programme with the participation of European Commission representatives and external invitees.
Read more
July 1st 2020
DisCoVeRy trial in practice
The DisCoVeRy clinical trial is an adaptive, randomized, open-label clinical trial, add-on of the Solidarity trial, that aims to evaluate the safety and efficacy of four antiviral therapeutic strategies as compared with standard of care. Patients are hospitalized in conventional departments or intensive care units both from academic or non-academic hospitals throughout Europe with COVID-19 [...]
Read more